Ensign Peak Advisors Inc Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Ensign Peak Advisors Inc lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 184.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 215,454 shares of the biotechnology company's stock after acquiring an additional 139,699 shares during the period. Ensign Peak Advisors Inc owned approximately 0.71% of AnaptysBio worth $2,853,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its position in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio in the 4th quarter worth about $40,000. AlphaQuest LLC grew its position in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after acquiring an additional 5,360 shares during the last quarter.

Analyst Ratings Changes

ANAB has been the topic of a number of research analyst reports. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Wolfe Research assumed coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target on the stock. Wells Fargo & Company upped their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Guggenheim upped their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Stock Performance

AnaptysBio stock traded up $0.25 during midday trading on Monday, reaching $20.47. 434,133 shares of the stock were exchanged, compared to its average volume of 600,682. The company's fifty day moving average is $18.97 and its 200-day moving average is $18.24. The firm has a market cap of $601.41 million, a PE ratio of -3.37 and a beta of -0.20. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a share buyback program on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.